Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 1693.

https://doi.org/10.1182/blood.V120.21.1693.1693

Published: 2012

Journal Articles

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Paolo Strati, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Elias J. Jabbour, MD, Aziz Nazha, Gautam Borthakur, Stefan Faderl, MD, Alfonso Quintás-Cardama, MD, Naval G. Daver, MD

Blood (2012) 120 (21): 1488.

https://doi.org/10.1182/blood.V120.21.1488.1488

Published: 2012

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, Lakshmikanth Katragadda, MD, Gabriela Rondon, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2001.

https://doi.org/10.1182/blood.V120.21.2001.2001

Published: 2012

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintás-Cardama, MD, Melanie Baccus, RN, Rebecca Garris, BSc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2012) 120 (21): 4308.

https://doi.org/10.1182/blood.V120.21.4308.4308

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

Kathy M. Tran, Hagop M. Kantarjian, MD, Syed M. Kazmi, MD, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Maro Ohanian, DO, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 4326.

https://doi.org/10.1182/blood.V120.21.4326.4326

Published: 2012

Journal Articles

The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia

Cristian Tomasetti, PhD, Hagop M. Kantarjian, MD, Ritesh Ramchandani, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Giovanni Parmigiani, PhD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4436.

https://doi.org/10.1182/blood.V120.21.4436.4436

Published: 2012

Journal Articles

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD, Alfonso Quintás-Cardama, MD

Blood (2012) 120 (21): 4434.

https://doi.org/10.1182/blood.V120.21.4434.4434

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

Journal Articles

Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, MD, Ohad Benjamini, MD, Sherry A. Pierce, RN, BS, Marylou Cardenas-Turanzas, Srdan Verstovsek, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 70.

https://doi.org/10.1182/blood.V120.21.70.70

Published: 2012

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Elias J. Jabbour, MD, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Alfonso Quintás-Cardama, MD, Rajyalakshmi Luthra, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2623.

https://doi.org/10.1182/blood.V120.21.2623.2623

Published: 2012

Journal Articles

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Rajyalakshmi Luthra, PhD, Susan o'Brien, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Stefan Faderl, MD, Marina Konopleva, M.D., Ph.D., William G. Wierda, MD, PhD, Elizabeth Burton, Jorge E. Cortes

Blood (2011) 118 (21): 454.

https://doi.org/10.1182/blood.V118.21.454.454

Published: 2011

Journal Articles

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis,

Alfonso Quintás-Cardama, MD, Hagop M Kantarjian, Gautam Borthakur, Zeev Estrov, Jorge E. Cortes, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 3863.

https://doi.org/10.1182/blood.V118.21.3863.3863

Published: 2011

Journal Articles

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, MD, Hagop Kantarjian, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, Stefan Faderl, MD, Pierce Sherry, Mark Brandt, Gautam Borthakur, Michael Keating, MD, Emil Freireich, Jorge E Cortes

Blood (2011) 118 (21): 2606.

https://doi.org/10.1182/blood.V118.21.2606.2606

Published: 2011

Journal Articles

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Joshua J Oaks, A. Mukhopadhyay, Ramasamy Santhanam, PhD, S. A Saddoughi, Paolo Neviani, PhD, Jason G Harb, Ph.D, Besim Ogretmen, PhD, Robert Bittman, Ph.D, Ross L Levine, MD, Alfonso Quintás-Cardama, MD, Guido Marcucci, MD, Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 2494.

https://doi.org/10.1182/blood.V118.21.2494.2494

Published: 2011

Journal Articles

Proteomic Profiling of 112 Proteins in Chronic Myeloid Leukemia Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Distinct Protein Expression Signatures Associated with Advanced Phase Disease and the CD34+ Compartment

Alfonso Quintás-Cardama, MD, Yi Hua Qiu, MD, Sean Post, Yiqun Zhang, Chad Creighton, Jorge E. Cortes, Steven M. Kornblau, MD

Blood (2011) 118 (21): 2503.

https://doi.org/10.1182/blood.V118.21.2503.2503

Published: 2011

Journal Articles

Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,

Alfonso Quintás-Cardama, MD, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, MD, Mark Brandt, BS, Sherry Pierce, RN, BS, Gautam Borthakur, Jorge E. Cortes

Blood (2011) 118 (21): 3594.

https://doi.org/10.1182/blood.V118.21.3594.3594

Published: 2011

Journal Articles

Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Michael S Mathisen, Hagop M Kantarjian, Elias Jabbour, MD, Guillermo Garcia-Manero, Farhad Ravandi, MD, Stefan Faderl, MD, Gautam Borthakur, Jorge E. Cortes, Alfonso Quintás-Cardama, MD

Blood (2011) 118 (21): 4256.

https://doi.org/10.1182/blood.V118.21.4256.4256

Published: 2011

NARROW

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP)

Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis,

Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia Over the Last 5 Decades At M.D. Anderson Cancer Center

FTY720 Restores PP2A Tumor Suppressor Activity in Polycythemia Vera CD34 + Progenitors Through Inhibition of Jak2 V617F- and PI-3Kγ-Dependent SET Serine Phosphorylation and Enhancement of NOS-Dependent PP2A Tyrosine Nitration

Proteomic Profiling of 112 Proteins in Chronic Myeloid Leukemia Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Distinct Protein Expression Signatures Associated with Advanced Phase Disease and the CD34+ Compartment

Impact of Npm1, Flt3, and Ras Mutations on the Outcomes of Elderly Patients with Acute Myeloid Leukemia,

Clofarabine-Containing Chemotherapy Does Not Increase the Risk of Infectious Complications in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only